文献速递物质与行为成瘾

阿片使用障碍新兴治疗临床试验设计的挑战与机遇:综述

Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review.
PubMed 文献 · JAMA Psychiatry · 2023-01-01

本综述由ACTTION与FDA合作召开会议,讨论针对μ-阿片受体系统以外靶点的阿片使用障碍新兴治疗(如大麻素类、致幻剂、镇静催眠药和免疫治疗)的临床试验设计。文章提出关于治疗阶段、治疗角色、主要结局和不良事件等关键设计要素的共识建议,强调纳入患者偏好和有经验者意见可加速有效安全疗法的开发与转化。

要点

  • 新兴治疗针对μ-阿片受体以外靶点,需明确治疗阶段(如寻求治疗、早期戒断/脱毒、长期康复)。
  • 治疗角色需界定为现有阿片使用障碍治疗的辅助或独立治疗。
  • 主要结局应基于患者偏好,评估阿片使用(含使用模式变化)、治疗保留和/或整体功能与生活质量。

核心结论

  • 应用本综述推荐并在设计阶段考虑有经验者的意见,将加速阿片使用障碍有效安全疗法的开发、转化和 uptake。

主要发现

  • 提出了关于新兴阿片使用障碍治疗试验设计最关键要素的共识建议,涵盖治疗阶段、治疗角色、主要结局和不良事件。

关键数值与推荐

  • 治疗阶段应明确靶向阶段(如寻求治疗、早期戒断/脱毒、长期康复)。
  • 治疗角色应明确为辅助现有阿片使用障碍治疗或独立于现有治疗。
  • 主要结局应基于患者偏好,评估阿片使用(包括使用模式变化)、治疗保留和/或整体功能与生活质量。
  • 不良事件应包括阿片相关复发或过量的潜在风险,尤其在不同时使用μ-阿片受体激动剂或拮抗剂维持治疗时。

临床怎么用

  • 在设计阿片使用障碍新兴治疗试验时,应明确治疗阶段、治疗角色、基于患者偏好的主要结局及不良事件监测。
  • 应特别关注未同时接受μ-阿片受体激动剂或拮抗剂维持治疗患者的阿片相关复发或过量风险。
  • 在设计阶段纳入有阿片使用障碍亲身经历者的意见。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Novel treatments for opioid use disorder (OUD) are needed to address both the ongoing opioid epidemic and long-standing barriers to existing OUD treatments that target the endogenous μ-opioid receptor (MOR) system. The goal of this review is to highlight unique clinical trial design considerations for the study of emerging treatments for OUD that address targets beyond the MOR system. In November 2019, the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the US Food and Drug Administration sponsored a meeting to discuss the current evidence regarding potential treatments for OUD, including cannabinoids, psychedelics, sedative-hypnotics, and immunotherapeutics, such as vaccines. OBSERVATIONS: Consensus recommendations are presented regarding the most critical elements of trial design for the evaluation of novel OUD treatments, such as: (1) stage of treatment that will be targeted (eg, seeking treatment, early abstinence/detoxification, long-term recovery); (2) role of treatment (adjunctive with or independent of existing OUD treatments); (3) primary outcomes informed by patient preferences that assess opioid use (including changes in patterns of use), treatment retention, and/or global functioning and quality of life; and (4) adverse events, including the potential for opioid-related relapse or overdose, especially if the patient is not simultaneously taking maintenance MOR agonist or antagonist medications. CONCLUSIONS AND RELEVANCE: Applying the recommendations provided here as well as considering input from people with lived experience in the design phase will accelerate the development, translation, and uptake of effective and safe therapeutics for individuals struggling with OUD.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kiluk BD, Kleykamp BA, Comer SD, et al. Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review. JAMA Psychiatry. 2023. PMID: 36449315. doi:10.1001/jamapsychiatry.2022.4020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。